Literature DB >> 12969770

Kinins are involved in the development of allergic nasal hyperresponsiveness in guinea pigs.

Shingo Sugahara1, Takeshi Nabe, Nobuaki Mizutani, Hiroshi Takenaka, Shigekatsu Kohno.   

Abstract

We evaluated roles of kinins in allergen-induced nasal blockage and sneezing, and development of nasal hyperresponsiveness to leukotriene D4 in a Japanese cedar pollen-induced allergic rhinitis model of guinea pigs. Sensitised guinea pigs were repeatedly challenged by pollen inhalation once every week. Neither a bradykinin B1 receptor antagonist, des-Arg9-[Leu8]bradykinin nor a bradykinin B2 receptor antagonist, icatibant suppressed allergen-induced sneezing and nasal blockage. However, development of nasal hyperresponsiveness to leukotriene D4 was significantly suppressed by them. The amount of bradykinin in nasal cavity lavage fluid was immediately increased after the challenge. In non-sensitised animals, hyperresponsiveness to leukotriene D4 was developed by a bradykinin B2 receptor agonist, bradykinin, but not by a bradykinin B1 receptor agonist, des-Arg10-kallidin, while in the sensitised-challenged animal, both agonists developed hyperresponsiveness. In conclusion, the nasal hyperresponsiveness appeared to be induced by kinins produced in response to the antigen challenge through activation of not only bradykinin B2 but also B1 receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969770     DOI: 10.1016/s0014-2999(03)02185-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.

Authors:  Gregory D Scott; Allison D Fryer
Journal:  Chem Immunol Allergy       Date:  2012-06-26

2.  Essential Contribution of CD4+ T Cells to Antigen-Induced Nasal Hyperresponsiveness in Experimental Allergic Rhinitis.

Authors:  Tomoe Nishimura; Osamu Kaminuma; Mayumi Saeki; Noriko Kitamura; Kunie Matsuoka; Hiromichi Yonekawa; Akio Mori; Takachika Hiroi
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.